This month Agilent Technologies will begin shipping its UltraVision release, an updated version of its Sonos 4500 and 5500 digital echocardiography systems. The product’s debut at last month’s Society of Echocardiography meeting in Chicago was
This month Agilent Technologies will begin shipping its UltraVision release, an updated version of its Sonos 4500 and 5500 digital echocardiography systems. The products debut at last months Society of Echocardiography meeting in Chicago was encouraging, said Kevin Appareti, Agilents product marketing manager.
Power modulation, Agilents new digital signal-processing technique, which increases the signal-to-noise ratio and improves tissue harmonic imaging and contrast imaging, is featured in the systems. The technology improves myocardial contrast enhancement, which allows researchers to see microcirculation and wall motion simultaneously, according to the firm.
The systems will also include the s3 transducer, which has extremely wide bandwidth and enhanced depth of field. The 4500 model is designed for clinics with a high volume, while the 5500 model can be used for clinical and research work, Appareti said.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.